Literature DB >> 21704526

Phenylpropenamide derivatives: anti-hepatitis B virus activity of the Z isomer, SAR and the search for novel analogs.

Peiyuan Wang1, Devan Naduthambi, Ralph T Mosley, Congrong Niu, Phillip A Furman, Michael J Otto, Michael J Sofia.   

Abstract

Phenylpropenamides have been reported to be a class of non-nucleoside inhibitors of the hepatitis B virus (HBV). This class of compounds was explored with the objective of developing potent anti-HBV agents, with a novel mechanism of action, that could be combined with nucleos(t)ide analogs currently used to treat HBV infection. To accomplish this objective a series of substituted arylpropenamide derivatives were prepared and the E and Z geometrical isomers were separated. The structural identity of each of the E and Z isomers was determined by single crystal X-ray crystallography. Contrary to previous reports, the activity of this class of molecules resides in the Z isomer. Further structure-activity relationship studies around the active Z isomer identified compounds that displayed potent antiviral activity against HBV with EC(90) value of approximately 0.5 μM in vitro. Attempts to develop ring constrained analogs did not lead to active HBV inhibitors.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704526     DOI: 10.1016/j.bmcl.2011.05.077

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  7 in total

1.  Evolution of Intermediates during Capsid Assembly of Hepatitis B Virus with Phenylpropenamide-Based Antivirals.

Authors:  Panagiotis Kondylis; Christopher J Schlicksup; Sarah P Katen; Lye Siang Lee; Adam Zlotnick; Stephen C Jacobson
Journal:  ACS Infect Dis       Date:  2019-02-04       Impact factor: 5.084

2.  4-Oxooctahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators.

Authors:  Nicky Hwang; Haiqun Ban; Shuo Wu; Kelly McGuire; Ellen Hernandez; Junjun Chen; Qiong Zhao; Manasa Suresh; Benjamin Blass; Usha Viswanathan; John Kulp; Jinhong Chang; Jason Clement; Stephan Menne; Ju-Tao Guo; Yanming Du
Journal:  Bioorg Med Chem Lett       Date:  2021-12-31       Impact factor: 2.823

3.  Assembly-directed antivirals differentially bind quasiequivalent pockets to modify hepatitis B virus capsid tertiary and quaternary structure.

Authors:  Sarah P Katen; Zhenning Tan; Srinivas Reddy Chirapu; M G Finn; Adam Zlotnick
Journal:  Structure       Date:  2013-07-18       Impact factor: 5.006

4.  Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids.

Authors:  Matthew R Campagna; Fei Liu; Richeng Mao; Courtney Mills; Dawei Cai; Fang Guo; Xuesen Zhao; Hong Ye; Andrea Cuconati; Haitao Guo; Jinhong Chang; Xiaodong Xu; Timothy M Block; Ju-Tao Guo
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

5.  Structures of Hepatitis B Virus Core- and e-Antigen Immune Complexes Suggest Multi-point Inhibition.

Authors:  Elif Eren; Norman R Watts; Altaira D Dearborn; Ira W Palmer; Joshua D Kaufman; Alasdair C Steven; Paul T Wingfield
Journal:  Structure       Date:  2018-08-09       Impact factor: 5.006

Review 6.  Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis.

Authors:  Debajit Dey; Manidipa Banerjee
Journal:  J Clin Transl Hepatol       Date:  2016-09-25

7.  Design, synthesis and in vivo anti-inflammatory activities of 2,4-diaryl-5-4H-imidazolone derivatives.

Authors:  Moustafa El-Araby; Abdelsattar Omar; Hassanein H Hassanein; Abdel-Ghany H El-Helby; Asharf A Abdel-Rahman
Journal:  Molecules       Date:  2012-10-18       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.